According to our recent payer coverage analysis for epilepsy treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.
To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.
Payer Coverage: A review of market access for epilepsy treatments shows that almost 29% of the covered lives under the pharmacy benefit in commercial formularies have utilization management restrictions on epilepsy medications.
Trends: Epidiolex, the first FDA-approved treatment that contains a purified drug substance derived from marijuana, is now available in the U.S. Via AIS Health.